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Posttranslational modifications can have profound effects on the
biological and biophysical properties of proteins associated with
misfolding and aggregation. However, their detection and quan-
tification in clinical samples and an understanding of the mecha-
nisms underlying the pathological properties of misfolding- and
aggregation-prone proteins remain a challenge for diagnostics
and therapeutics development. We have applied an ultrasensitive
immunoassay platform to develop and validate a quantitative
assay for detecting a posttranslational modification (phosphoryla-
tion at residue T3) of a protein associated with polyglutamine
repeat expansion, namely Huntingtin, and characterized its pres-
ence in a variety of preclinical and clinical samples. We find that
T3 phosphorylation is greatly reduced in samples from Hunting-
ton’s disease models and in Huntington’s disease patients, and we
provide evidence that bona-fide T3 phosphorylation alters Hun-
tingtin exon 1 protein conformation and aggregation properties.
These findings have significant implications for both mechanisms
of disease pathogenesis and the development of therapeutics and
diagnostics for Huntington’s disease.
huntingtin | posttranslational modification | immunoassay |
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Posttranslational modifications (PTMs) likely evolved as astrategy to flexibly modulate protein structure and function in
response to developmental, homeostatic, or physiological re-
quirements without the need to exert permanent changes at the
genetic level (1). In recent years, it has become apparent that
PTMs are extremely diverse and widespread and decorate pro-
teins at multiple sites, thus increasing exponentially the capacity
for adoption of multiple structural and functional states of a
protein (2). Many neurodegenerative diseases are associated
with accumulation and misfolding of specific proteins (3, 4),
often associated with changes in PTM status. Some PTMs such
as phosphorylation can have profound influences on the struc-
ture, function, and pathology-related properties of proteins as-
sociated with neurodegeneration [for example, TAU, Androgen
Receptor, and Huntingtin (5–10)]. Their modulation therefore
represents an attractive candidate therapeutic approach (7, 8,
11). However, the transient character of most PTMs presents a
challenge for the development of assays to detect, monitor, and
quantify PTMs, thus impeding the identification of mechanisti-
cally relevant PTMs, the establishment of their role in disease
pathogenesis, and the discovery of their modulators.
Huntington’s disease (HD) is a progressive, autosomal-dominant
neurodegenerative disease caused by a triplet repeat expansion
mutation within exon 1 of the huntingtin gene (HTT) (12;
reviewed in ref. 13). The mutation leads to the production of
huntingtin protein (HTT) bearing a polyglutamine expansion
(polyQ) within its amino terminus (N-term). Consistent with a
determinant role in the pathology, the size of the polyQ expansion
demonstrates a strong inverse correlation with the age-of-onset
of the characteristic clinical (motor, psychiatric, and cognitive)
symptoms (14, 15). The CAG repeat/polyQ expansion is believed
to cause pathology primarily through a gain-of-function, which
imparts novel characteristics on mutant HTT, including the pro-
duction of N-terminal fragments, likely through aberrant mRNA
splicing as well as proteolytic events (16, 17). Mutant HTT N-term
fragments have been described to misfold and form detectable
aggregates, and their overexpression has been reported to re-
produce several aspects of HD in animal models (18–21; reviewed
in ref. 22). The expansion of the polyQ domain associated with
the HD mutation was recently shown to alter the conformation
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of the N-term region of HTT (23–25). Interestingly, regions
flanking the polyQ domain, including the first 17 N-terminal
amino acids of HTT (N17) and a polyproline-rich C-terminal to
the polyQ region, have been shown to influence the propen-
sity of short N-term HTT fragments to misfold and aggregate
(26–30). Recent studies demonstrated that phosphomimetic
mutations at specific residues (S13/S16) within the N17 region
can modulate the subcellular localization, stability, aggregation,
and toxicity properties of mutant HTT in different preclinical
models (29, 31–33), raising interest in these PTMs as possible
modifiers of mutant HTT biological and biophysical proper-
ties. Significantly, studies on HTT exon 1-like peptides bearing
phosphorylated S13/16 residues or S/D mutations at the same
residues demonstrated substantially reduced aggregation in
vitro compared with the unphosphorylated or wild-type (WT)
counterparts, suggesting that N17 phosphorylation modulates
the capacity of mutant HTT N-term fragments to self-assemble
and aggregate (34–36). Thus, increasing HTT N17 phosphory-
lation may represent a meaningful therapeutic approach aimed
at ameliorating the toxic properties of mutant huntingtin.
However, a critical requirement to address this hypothesis is the
availability of quantitative, sensitive assays to measure N17 HTT
phosphorylation and identify genetic and/or pharmacological
modulators for proof-of-concept studies, as well as to monitor
HTT N17 phosphorylation in different HD models and, ulti-
mately, in HD patients. To date, HTT phosphorylation has been
predominantly studied by either mass spectrometry approaches
or Western blotting (WB) (32, 33, 37–42). Phosphorylation at T3
(pT3) appears to be the most readily observable N17 phos-
phorylation site, at least with current tools and in the preclinical
models examined (39, 40). Additionally, pT3 has been reported
to interfere with aggregation of purified mutant HTT exon
1 protein (36), suggesting that its modulation may impact a
pathologically relevant aspect of HD, namely mutant HTT mis-
folding and aggregation. However, further analysis of this PTM’s
relevance for HD and functional/mechanistic studies require the
capacity to quantitatively and sensitively measure this PTM in
preclinical and clinical samples, which is extremely challenging
with current methods. Therefore, we developed a quantitative
immunoassays to detect and quantify phosphorylation on HTT
N17, starting with pT3 and leveraging the availability of semi-
synthetic HTT exon 1 proteins bearing a bona-fide pT3 modifi-
cation (35) in both WT and mutant forms, as well as a
corresponding anti-pT3 HTT antibody, which we previously
characterized (35, 40). Importantly, these pg/mL assays un-
covered a strong effect of polyQ expansion on pT3 HTT levels in
mutant HTT in HD cells, HD mice, and HD patients and in-
dicate that the presence of a mutant polyQ results in greatly
decreased immunoreactive T3 phosphorylation on HTT. Mech-
anistically, using semisynthetic HTT exon 1 (HTT EX1) proteins,
we provide evidence that phosphorylation on HTT T3 can in-
fluence the conformation and decrease the aggregation proper-
ties of mutant HTT in vitro, consistent with other findings
reported elsewhere (36). Collectively, our data point to resto-
ration of pT3 levels in mutant HTT as a therapeutically relevant
candidate approach for HD and enable investigations aimed at
identifying genetic and pharmacological modulators of phos-
phorylation on T3 in HTT protein.
Results
Development of a Singulex-Based Immunoassay for Huntingtin pT3
and Specific Detection of Huntingtin T3 Phosphorylation in Cells.
Immunoassay development requires the availability of anti-
bodies capable of specifically recognizing the epitopes of inter-
est and availability of the purified antigen protein to assess
specificity and sensitivity in a controlled context. Recently, we
reported the development of semisynthetic strategies that en-
abled the generation of HTT EX1 proteins with bona-fide
phosphorylation on residue T3 (pT3) as well as a rabbit poly-
clonal antibody (pAb) specific for pT3 HTT (35, 40). We were
therefore in a position to attempt the development of quantita-
tive immunoassays to detect and measure levels of pT3 in HTT
protein in different biological contexts using these reagents (Fig.
1 A and B). Because a specific PTM may affect only a fraction of
the total cellular steady-state pool of the protein of interest, we
turned to one of the most sensitive immunoassay platforms
available (43), an application of which was recently employed to
develop an ultrasensitive immunoassay for detection of mutant
HTT in cerebrospinal fluid (44). The assay is essentially a
quantitative fluorescent sandwich immunoassay coupled to
single-molecule counting technology (Singulex Erenna immu-
noassay). Two antibodies are therefore required (one for capture
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Fig. 1. Profiling of anti-pT3 HTT antibody. (A) The
pT3 signal is specific for the presence of a phos-
phorylated T3 residue. Western immunoblotting
profiling of anti-pT3 antibody on semisynthetic HTT
Q23 EX1 protein, HTT EX1 Q23 protein with phos-
phorylated T3 residue, and the same proteins treated
with alkaline phosphatase. (B) The anti-pT3 antibody
detects a specific signal on WT HTT EX1 Q16 over-
expressed in HEK293T cells lysates, but not on the
T3A mutant form by Western immunoblotting
analysis. (C) Diagram illustrating the position (i) and
epitopes (ii) of antibodies used in the present study.
(D) Strategy adopted for the development of sand-
wich assays specific for total HTT and pT3 HTT,
employing antibody MW1 as a capture antibody for
both HTT forms.
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and one for detection; Fig. 1D). As the purified antigen protein
was the protein encoded by the first exon of HTT (35), antibody
choice for assay development was limited to antibodies with
epitopes within the protein encoded by HTT exon 1 (Fig. 1 C, i
and ii). Importantly, an immunoassay capable of measuring
pT3 levels needs to be coupled to a companion immunoassay for
the measurement of overall HTT levels (“total HTT”) to allow
for normalization of pT3 levels. The two immunoassays (pT3-
specific and total HTT-specific) ideally need to be based on the
same capture antibody, to enable meaningful comparisons be-
tween pT3 HTT and total HTT levels (Fig. 1D). A mouse
monoclonal antibody (mAb) specific for a polyQ repeat, MW1
(45, 46), was selected as the capture antibody for both pT3 HTT
and total HTT immunoassays. MW1 displays an apparently
higher affinity for HTT bearing expanded (mutant) polyQ re-
peats, but can efficiently detect HTT bearing WT polyQ repeats
under native conditions (24, 25, 46), a finding that we confirmed
in the Singulex Erenna immunoassay (Fig. 2B and Fig. S1 A and
B). Importantly, we observed an attenuated difference in ap-
parent affinity for expanded (mutant) HTT protein relatively to
unexpanded polyQ (wild type) HTT protein when the MW1 was
used as a capture Ab (although a degree of selectivity for ex-
panded polyQ is still retained) in the Singulex Erenna immu-
noassay, as opposed to the same Ab used as a detection Ab (as
employed by ref. 44) (Fig. S1), thus validating the use of MW1 as
an antibody allowing detection of both WT and mutant HTT in
these experimental conditions. The anti-pT3 HTT pAb pre-
viously characterized was selected as the detection antibody for
the pT3 HTT immunoassay, while 2B7 (a mouse mAb specific
for an epitope within the N17 HTT domain) (47) was selected as
the detection antibody for the total HTT immunoassay (Fig. 1C).
We then asked if MW1/2B7 and MW1/pT3 combinations were
able to specifically detect HTT EX1 proteins of known purity
and concentration bearing no phosphorylation, a phosphorylated
T3 residue (pT3), or the same pT3 protein subjected to phos-
phatase treatment. A serial dilution of each protein was pro-
duced and analyzed using the Singulex Erenna platform with the
MW1/pT3 antibody pair (Fig. 2A) or with the MW1/2B7 pair
(Fig. 2B). The MW1/pT3 pair was clearly able to detect HTT
EX1 bearing a pT3 residue, but not the phosphatase-pretreated
protein or its unphosphorylated equivalent, thus demonstrating
specificity toward pT3 (Fig. 2A). Key parameters for the MW1/
pT3 and MW1/2B7 Singulex immunoassays, namely Limit of
Detection (LoD), Lower Limit of Quantification (LLoQ), and
Upper Limit of Quantification (ULoQ) (48) are summarized in
Fig. 2 A and B. Collectively, the data obtained using purified
HTT EX1 proteins indicated that the MW1/pT3 and MW1/2B7
Singulex immunoassays were specific, sensitive, and robust. The
specificity of the MW1/pT3 and MW1/2B7 Singulex immunoas-
says was next tested in HEK293T cells through RNAi (knock-
down of HTT expression on pT3 HTT and total HTT levels
under endogenous or transfected HTT expression) or through
specific mutation (effects of T3A mutation on pT3 HTT and
total HTT levels with HTT expressed from a plasmid construct).
Endogenous HTT expression in HEK293T cells is detectable by
WB (Fig. 3A), and these cells have been widely employed to
study various huntingtin and mutant huntingtin characteristics,
including its phosphorylation status (37, 40, 42). First, we in-
vestigated the effects of RNAi [using either a siRNA targeting a
specific HTT sequence or a scrambled, control (CTRL) siRNA]
on HTT and pT3 HTT protein levels in HEK293T expressed
from the endogenous HTT locus or from a transiently transfected
plasmid construct expressing a full-length HTT Q18 cDNA. The
efficiency of knockdown of endogenous HTT mRNA levels was
verified by quantitative real-time PCR (Fig. S2A). As shown in
Fig. 3A, HTT protein expression was clearly detected in WB by
MAB2166, a specific anti-HTT monoclonal antibody widely
employed to detect HTT in different samples (49–53), and was
specifically reduced in cells transfected with the HTT-specific
siRNA, as confirmed by densitometric analysis (Fig. S2B). Endog-
enously expressed HTT protein is phosphorylated on T3 as de-
tected in WB by the anti-pT3 pAb. A reduction was observed in
cells transfected with the specific HTT siRNA, thus further con-
firming the specificity of the anti-pT3 pAb. We then interrogated
these lysates using the MW1/pT3 and MW1/2B7 Singulex immu-
noassays to examine the effects of specific genetic knockdown of
HTT expression. As shown in Fig. 3B, comparable reductions in
pT3 HTT and total HTT protein levels were achieved using ge-
netic knockdown of HTT expression, irrespective of the context
(endogenous HTT or overexpressed HTT). These results indicated
that the signal obtained from the MW1/pT3 and MW1/2B7 im-
munoassays in a biological matrix is specific for pT3 HTT and
total HTT proteins, respectively.
Next, we interrogated the effect of a specific T3 mutation
(T3A), abrogating the possibility of phosphorylation on HTT T3,
on the signal obtained from the MW1/pT3 and MW1/
2B7 immunoassays. As HEK293T cells bearing endogenous T3A
HTT alleles are not available, we opted for a transient trans-
fection context. Plasmid constructs encoding HTT EX1 with
different polyQ repeats representing a WT expansion (Q16), an
HD expansion (Q39), a juvenile-type HD expansion (Q72), or
their T3A variants were transiently expressed in HEK293T cells.
The specificity of the anti-pT3 pAb was first confirmed by Phos-
Tag SDS/PAGE WB (Fig. 3C), as previously shown using HTT
EX1-EGFP fusions in the same cell line (40). HTT EX1 protein
levels were assessed using 4C9, a monoclonal Ab specific for the
polyproline repeat domain (Fig. 3C) (47). Using these lysates, we
determined the effect of the T3A mutation on pT3 HTT and
total HTT signal obtained with the Singulex MW1/pT3 and
MW1/2B7 immunoassays, respectively. The presence of the T3A
mutation in the transiently transfected HTT EX1 constructs
resulted in a strong reduction of pT3 HTT levels without any
effect on total HTT levels (Fig. 3D and Fig. S2C), which was
significant for all tested polyQ repeat lengths. Collectively, the
data indicated that the Singulex MW1/pT3 and MW1/2B7
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Fig. 2. Performance of MW1/pT3 and MW1/2B7 Singulex immunoassays. (A)
Performance of the MW1/pT3 Singulex immunoassay examined using serial
dilutions of semisynthetic HTT EX1 Q23 protein, HTT EX1 Q23 bearing a
phosphorylated T3 residue, and HTT EX1 Q23 bearing a phosphorylated
T3 residue treated with alkaline phosphatase. The pT3 signal is proportional
to the concentration of HTT EX1 Q23 pT3 protein and is sensitive to alkaline
phosphatase treatment. Limits of detection and quantification are indicated.
(B) Performance of the MW1/2B7 Singulex immunoassay examined using
serial dilutions of the same proteins. Comparable levels of the three proteins
are detected. Limits of detection and quantification are indicated.
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immunoassays were sufficiently specific and sensitive to allow
investigations of pT3 HTT levels in biological samples of rele-
vance to HD.
Huntingtin T3 Phosphorylation Is Strongly Decreased in HD Mice and
in Human HD Samples. We first examined the effect of expanded
polyQ on pT3 HTT levels in the brain, using the Hdh
Q111 mouse model (54–56) where the mouse exon 1 sequence
has been replaced with a human exon 1 sequence with either a
Q7 or a Q111 repeat (Q7/Q111 and Q111/Q111; HD mouse
strains). Mutant huntingtin is therefore expressed in a fully
physiological manner. Two brain regions (cortex and cerebel-
lum) were investigated from 6-mo-old mice (an age at which
EM48-positive nuclear inclusions are not yet detectable) (54,
55). Animals included four homozygous WT (Q7/Q7) mice, six
heterozygous mutant (Q7/Q111) mice, and one homozygous
mutant (Q111/Q111) mouse. pT3 HTT and total HTT levels
were interrogated by SDS/PAGE WB analysis and by Singulex
immunoassays. Levels of pT3 HTT as detected by the anti-
pT3 pAb in SDS/PAGEWB are clearly decreased in brain cortex
from heterozygous Q7/Q111 and homozygous Q111/Q111 mice
compared with WT (Q7/Q7) mice, despite comparable total
soluble huntingtin protein levels as detected by MAB2166 (epi-
tope amino acids 442–457; Fig. 4A) or the monoclonal antibody
D7F7 (epitope around amino acid 1,220; Fig. S3A, i). The ex-
panded polyQ allele was correctly detected by MW1 in brain
cortex from heterozygous and homozygous mutant mice but not
in cortex from WT mice (Fig. 4A) (46). Coherent results were
obtained in pooled whole brains from WT (Q7/Q7) mice and
mutant (Q7/Q111) mice (Fig. S3B). Next, pT3 and total HTT
levels were assessed using the MW1/pT3 (Fig. S4 A, i) and the
companion MW1/2B7 Singulex immunoassay (Fig. S4 A, ii) in
a brain cortex sample. To exclude a possible confounding in-
fluence of known HTT PTMs on total HTT detection using
2B7, two additional total HTT Singulex immunoassays were
employed, based on MAB2166 (epitope amino acids 442–457;
Figs. S4 A, iii and S3C) or HDB4E10 (epitope amino acids
1,831–2,131; Figs. S3C and S5A). All three total HTT immu-
noassays (MW1/2B7, MW1/MAB2166, and MW1/HDB4E10),
independent of the detection antibody employed, displayed
higher total HTT signals in heterozygous mutant samples than
in WT samples, consistent with a degree of selectivity for ex-
panded polyQ displayed by MW1 when used as a capture an-
tibody in these assays (Figs. S4 and S5). Importantly, upon
normalization of pT3 signal for total HTT signal (irrespective
of the anti-HTT detection antibody used to measure total HTT
in the Singulex assay), the analysis confirms a robust decrease
of pT3 immunoreactivity when polyQ is expanded (Fig. 4 and
Fig. S5B), consistent with WB data. The specificity of the
pT3 signal detected in Q7/Q7 and Q7/Q111 brain samples was
confirmed by immunodepleting HTT protein using 2B7 (Fig.
S6A) and then assessing pT3 HTT and total HTT levels in the
Q7/Q7 and in Q7/Q111 contexts (Fig. S6 B and C, respectively)
where immunodepletion resulted in a clear, comparable de-
crease of MW1/pT3 and MW1/MAB2166 signals relative to
controls. We also assessed an independently produced and
previously characterized rabbit pAb specific for pT3 HTT (39)
in the same assay platform, using MW1 as a capture Ab and the
anti-pT3 Ab as the detection Ab. This alternative pT3 HTT
Singulex immunoassay behaved comparably to the MW1/pT3
Singulex immunoassay under all conditions tested (Fig. 4C and
Fig. S4). To determine if the difference in pT3 HTT levels is
observable in another brain area, we investigated the cerebel-
lum from these mice by both WB (Fig. 5 A, i; see also Fig. S3A
for total HTT detection using the alternative anti-HTT anti-
body, D7F7) and Singulex immunoassays (Fig. 5 A, ii and Fig.
S7A) and found comparable results as those obtained in mouse
cortex. The striatum was also investigated with similar results
(Fig. S8). We also investigated pT3 HTT levels in cortex from
knock-in Hdh mice bearing a humanized HTT exon 1 with
different polyQ expansions (Q7, Q20, Q50, Q92, and Q111; Fig.
5 B, i and ii and Fig. S7B) to confirm data obtained in Q7/Q7 and
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Fig. 3. Specificity of the MW1/pT3 and MW1/2B7 Singulex immunoassays. (A) Western immunoblot of HEK293T protein lysates demonstrating the effects of
HTT mRNA knockdown using a specific HTT siRNA on endogenous and overexpressed full-length (FL) HTT for both pT3 HTT and total HTT protein levels. (B)
Singulex analysis using MW1/pT3 or MW1/2B7antibody combinations showing the effects of HTT RNA knockdown on endogenous HTT levels (i) and on HTT
protein levels obtained in cells transfected with a plasmid encoding a full-length HTT Q18 cDNA (ii). Data demonstrate that signals from both assays are
sensitive to specific HTT expression knockdown. Means and SD of three independent experiments, paired t-test (two-tailed; *P < 0.05; **P < 0.01). (C) Western
immunoblot of Phos-Tag SDS/PAGE, representing HEK293T cells transfected with each HTT EX1 plasmid construct bearing different CAG repeats with or
without a T3A mutation and probed either with anti-pT3 pAb or with mAb 4C9. The HTT pT3 signal is sensitive to the T3A mutation. (D) Singulex immu-
noassay detecting effects of the T3A mutation on relative HTT pT3 levels in lysates from HEK293T cells expressing HTT EX1 constructs bearing different polyQ
repeats. Means and SD of at least four independent experiments, paired t-test (two-tailed; *P < 0.05; **P ≤ 0.01).
E10812 | www.pnas.org/cgi/doi/10.1073/pnas.1705372114 Cariulo et al.
Q7/Q111 mice. As shown in Fig. 5 B, ii, normalized pT3 levels
are clearly decreased in the presence of a polyQ expansion of
Q50 or greater. Therefore, pT3 levels in the brain of mice
expressing a mutant huntingtin protein are decreased relatively
to the same brain region of mice expressing WT huntingtin
protein. As this effect is observed on the denatured protein
(SDS/PAGE) as well as on the native protein (Singulex im-
munoassay), it is likely due to a bona-fide decrease in phos-
phorylation levels on the residue rather than a conformational
change masking the pT3 epitope as a result of polyQ repeat
expansion.
The findings in Hdh Q111 mice prompted us to interrogate
HD samples of human origin to determine if the effect of mutant
polyQ on HTT pT3 levels observed in animal models is relevant
to human HD. Recently, the HD consortium reported the gen-
eration of induced pluripotent stem cell (iPSC) lines from HD
patients and controls (57). A number of these iPSC lines can be
differentiated into a neuronal phenotype, including striatal
projection neurons (58). These cells may therefore represent a
physiologically relevant human cellular model of HD. We de-
cided to investigate if pT3 HTT levels differed significantly in
neuronally differentiated cultures from two HD iPSC lines
(Q109 and Q60) and three control iPSC lines (Q21, Q28, and
Q33). Following Singulex immunoassay analysis of lysates from
these samples (Fig. S9), relative pT3 HTT levels were signifi-
cantly lower in differentiated cultures from HD iPSCs than in
control iPSCs (Fig. 6A). This finding, obtained in one of the most
translationally relevant preclinical HD models, led us to in-
vestigate HTT pT3 levels directly in clinical samples. To this
extent, a small test cohort of peripheral blood mononuclear cell
(PBMC) samples was collected from control individuals or from
clinically characterized HD patients (Fig. 6B and Fig. S10), as
described previously (41, 59). As shown in Fig. 6B, a clear rela-
tive decrease in HTT pT3 immunoreactivity was observed in HD
PBMCs. Therefore, mutant HTT appears to be hypophosphory-
lated relative to its WT counterpart across different preclinical
models and in human HD.
T3 Phosphorylation Affects the Conformation and Decreases the
Aggregation Properties of Mutant Huntingtin Exon 1. Having estab-
lished an association between HTT pT3 levels and the HD muta-
tion across multiple models, we asked if HTT T3 phosphorylation
influences HD pathology-relevant properties, such as the capacity
of mutant polyQ expansions to modulate HTT EX1 fragment
conformational properties and aggregation (60–62). Recently, we
and others reported on conformational effects imparted by the
polyQ expansion on soluble HTT proteins (23–25), aspects of
which can be meaningfully investigated with time-resolved fluo-
rescence energy transfer (TR-FRET)–based immunoassays (24,
25). Briefly, the ratio of the signals produced by the TR-FRET
antibody pair on HTT proteins at the two test temperatures is in-
versely proportional to the length of the polyQ repeat and is par-
alleled by a temperature-dependent change in the α-helicity of
HTT’s N terminus, which increases with increasing polyQ length
(24, 25). We therefore interrogated the effects of pT3 on
the conformation of semisynthetic HTT EX1 with WT (Q23) or
mutant (Q43) expansions using the 2B7/MW1 conformational
immunoassay, taking advantage of the recent availability of semi-
synthetic HTT EX1 with Q43. In this assay, pT3 had no significant
conformational effect on HTT EX1 Q23 as detected by the 2B7/
MW1 TR-FRET immunoassay, with the temperature ratio of the
2B7/MW1 signals from the pT3-modified HTT EX1 Q23 and the
unmodified HTT EX1 Q23 proteins being comparable (Fig. 7 A, i).
However, pT3 modification of the mutant EX1 HTT Q43 resulted
in a significant increase in the temperature ratio of the 2B7/
MW1 signals obtained from the EX1 HTT Q43 protein, approxi-
mately halving the conformational constraint imposed by the mu-
tant polyQ expansion (Fig. 7 A, ii). Interestingly, semisynthetic
HTT Q23 and Q43 proteins bearing another PTM associated with
HTT’s N17 region [acetylated K6, AcK6 or acetylated K9, AcK9
residues (32)] produced no effect irrespective of the length of the
polyQ region, suggesting that the observed conformational effect
is specific for pT3 (Fig. 7 A, i and ii). Additionally, a control TR-
FRET immunoassay [2B7/4C9, which does not interrogate the
polyQ region and is not sensitive to temperature and polyQ length
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Fig. 4. Mutant HTT is hypophosphorylated on residue T3 in Hdh Q111 knock-in HD mice cortex. (A) Western immunoblot of homogenates from Hdh knock-in
mouse (6-mo cortex), analyzed using anti-pT3 (for HTT pT3), mAb 2166 (for total HTT), and MW1 (for expanded polyQ) antibodies, showing that mutant HTT
is hypophosphorylated relative to its Q7 counterpart. (B) Relative HTT pT3 Singulex signal in brain cortex samples from WT (Q7/Q7) or heterozygous mutant
(Q7/Q111) Hdh HD animals, normalized to total HTT levels measured either with the MW1/2B7 Singulex immunoassay (i) or with the MW1/2166 Singulex
immunoassay (ii). Means and SD of four Q7/Q7 samples and six Q7/Q111 samples, unpaired t-test (two-tailed; **P < 0.01; ***P < 0.005). (C) Relative HTT pT3
(alternative anti-pT3 Ab from ref. 39) Singulex signal in brain cortex samples from WT (Q7/Q7) or heterozygous mutant (Q7/Q111) Hdh HD animals, nor-
malized to total HTT levels measured either with the MW1/2B7 Singulex immunoassay (i) or with the MW1/2166 Singulex immunoassay (ii). Means and SD of
four Q7/Q7 samples and six Q7/Q111 samples, unpaired t-test (two-tailed; **P < 0.01; ***P < 0.005).
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(24, 25)] did not produce temperature- and polyQ-dependent dif-
ferences in TR-FRET signals (Fig. 7B). These results suggest that
pT3 can influence mutant HTT EX1 conformation, apparently
ameliorating the conformational rigidity imparted by the mutant
polyQ expansion. In this light, pT3 might therefore be a pro-
tective modification. To further investigate this hypothesis, we
interrogated the effect of pT3 on semisynthetic mutant HTT
EX1 aggregation using a standard filter trap assay (63). A no-
table difference in the SDS-insoluble fraction present in
semisynthetic HTT EX1 Q43 and Q43 pT3 was detectable,
suggesting that the presence of T3 phosphorylation may reduce
aggregation in these semisynthetic proteins (Fig. 7C). A filter
trap analysis confirmed these observations, with a reduction of
HTT EX1 Q43 filter-retained material observed when the
protein was phosphorylated (Fig. 7 C, iii), consistent with data
obtained by other methodologies. As expected, HTT EX1
Q23 did not produce significant signal in the filter trap assay.
Collectively, these data suggest that T3 phosphorylation can
ameliorate the conformational constraint imposed by the HD
mutation on HTT protein and reduce aggregation, at least in
the in vitro context examined.
Discussion
Mutant HTT self-association and toxicity are believed to be
primary determinants of HD pathology (13). Accumulating evi-
dence indicates that the first 17 amino acids of HTT (N17) play a
key role in modulating mutant HTT toxicity (30, 64). This do-
main can adopt an α-helical structure (65–67) and appears to be
a key cis-acting modifier of polyQ aggregation (28), subcellular
localization, and toxicity (29, 31, 33, 68). The N17 domain can be
posttranslationally modified at several residues including pT3
(39) and S13/S16 (32, 33). Introduction of mutations that abol-
ish (S→A) or mimic (S→E/D) phosphorylation at S13 and
S16 residues has been shown to affect the conformation of
HTT’s N17 domain as well as subcellular localization, aggrega-
tion, and toxicity of mutant HTT (29, 33). Studies employing
HTT exon 1-like peptides containing pS13/pS16 have confirmed
the modulatory effects of phosphomimetic S13/S16 mutations on
HTT aggregation and suggest that pS13/pS16 may impart a
thermodynamic barrier to the initial phases of oligomerization by
interfering with the packing and stabilization of oligomers or by
affecting overall oligomer stability (34). The collective evidence
therefore argues that increasing or mimicking phosphorylation
within HTT N17’s domain reduces mutant HTT toxic properties
(29, 33, 69), and significant potential exists for therapeutic
strategies aimed at addressing HD through the modulation of
these PTMs. Despite this, our capacity for testing the hypothesis
that HD pathology can be modulated by leveraging HTT PTMs
is presently hindered by the paucity of quantitative, sensitive, and
robust assays capable of profiling these PTMs across disease
models, of confirming their relevance to human HD, and of
enabling the identification of genetic and pharmacological tools
for proof-of-concept studies.
We therefore set out to develop HTT assays to interrogate
HTT PTMs, focusing initially on phosphorylation of the N17
domain on residue T3. This HTT PTM was chosen for assay
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development for a number of reasons. First, by analogy with the
effects of S13 and S16 modification on HTT’s N17 structure and
function, it seemed plausible that phosphorylation of T3 may also
play a role in regulating HTT N17’s structure and function, and
indeed recent structural evidence argues that T3 is strategically
positioned to regulate α-helical content in the N17 domain of
HTT (70–72). Importantly, recent studies showed that pT3 in-
hibits the aggregation of mutant HTT Ex1 (36), and pT3 is the
phosphorylation event most readily detected in the N terminus of
HTT by mass spectrometry and WB, at least when HTT is
overexpressed in cells (39, 40). Also, HTT T3 phosphorylation
has been profiled previously in HD models by standard immu-
noblotting methods to a more detailed extent than other HTT
N17 phosphorylations (39). Finally, relevant tools such as semi-
synthetic HTT proteins bearing a phosphorylated T3 residue and
specific antibodies are available (35, 36, 39, 40).
The approach that we applied for pT3 immunoassay design
involved the Erenna Singulex sandwich immunoassay, a version
of which, based on 2B7 as a capture Ab and MW1 as a detection
Ab, was recently employed to develop an ultrasensitive immu-
noassay for detection of mutant HTT in cerebrospinal fluid (44).
Sandwich immunoassay design involved the concomitant devel-
opment of immunoassays for the detection of HTT pT3 and
“total” HTT based on the same capture antibody. Assay devel-
opment followed a standard approach and involved preliminary
assay qualification using reference standards of high purity and
known concentration (semisynthetic HTT EX1 proteins with/
without pT3), followed by a rigorous interrogation of assay
specificity using genetic means (specific RNA knockdown and
T3A mutations) in a simple cell-line context. Following devel-
opment and validation, the MW1/pT3 and MW1/2B7 Singulex
immunoassays were used to interrogate the relevance of
T3 phosphorylation for HD pathology, starting with the effect of
mutant polyQ expansion on pT3 levels. We have shown that
MW1 can efficiently bind native HTT-bearing WT polyQ ex-
pansions when used as a capture Ab in the Singulex Erenna
immunoassay and that under these conditions MW1’s reported
higher affinity for expanded polyQ is significantly attenuated.
When quantifying pT3 HTT levels in biological samples, we
opted to normalize the signal obtained with the MW1/pT3 Sin-
gulex Erenna immunoassay with the signal obtained as a measure
of total HTT protein present in the sample using the MW1/2B7
Ab combination, which employs the same Ab (MW1) as a cap-
ture IgG. We therefore obtained a pT3 HTT signal that is rel-
ative to total HTT measured in the same sample. Intersample
comparisons are then performed between relative pT3 HTT
levels, thus informing in a polyQ-normalized fashion on the
proportion of HTT phosphorylated on residue T3. Naturally,
several factors aside from absolute T3 phosphorylation levels
may influence apparent PTM levels detected by immunoassays
because of the intrinsic nature of the antibody–antigen in-
teraction. These include conformational aspects as well as the
presence of additional modifiers such as additional PTMs, which
we have tried to address using orthogonal approaches (e.g., the
use of WB and of multiple antibodies). Immunoreactive pT3
HTT levels were examined in one of the most widely employed
mouse models of HD, the Hdh Q111 mouse model (54, 55). In
brain cortex of Hdh mice, a thorough examination of pT3 HTT
levels was performed, comprising different normalization ap-
proaches toward total HTT (the selected MW1/2B7 pair plus
an alternative pair composed of the MW1/2166 combination),
the use of an alternative, independently developed anti-
pT3 pAb (39) for HTT pT3 detection, the demonstration of
specificity using an immunodepletion approach, and orthogonal
validation by WB. In brain cortex, immunoreactive pT3 HTT
levels were clearly decreased in Hdh Q7/Q111 and Q111/
Q111 mice relative to Q7/Q7 mice, a result that was mirrored in
another brain area, the cerebellum, and observed also in Hdh
mice bearing a humanized exon 1 with different mutant polyQ
expansions (Q50, Q92, and Q111) relative to mice bearing the
same transgene with WT polyQ expansions (Q7 or Q20). Next,
we decided to investigate if pT3 HTT levels differed significantly
in neuronally differentiated cultures from human iPSC lines
derived from control and HD individuals, as patient-derived
iPSC lines represent one of the most translationally relevant
preclinical HD models (73). Coherent with results obtained in
the mouse HD model, relative pT3 HTT levels were significantly
lower in differentiated cultures from HD iPSC than in control
iPSCs. Finally, we investigated HTT pT3 levels in a clinical
sample, the most accessible of which is PBMCs isolated from
peripheral blood. Although not representative of the CNS, these
peripheral samples can be employed to probe aspects of mutant
HTT pertinent to HD pathology (47). A clear decrease in im-
munoreactive HTT pT3 levels was observed in HD PBMCs rela-
tive to PBMCs from control individuals, thus confirming results
obtained in preclinical HD models.
Given the lower levels of apparent T3 phosphorylation in
mutant huntingtin relative to its WT counterpart in vivo,
we investigated the role of pT3 on mutant HTT behavior. We
and others have demonstrated that polyQ expansion results in
conformational changes in HTT proteins, either purified or
expressed in cells, which can be detected by TR-FRET immu-
noassays (24, 25). Using this conformational TR-FRET immu-
noassay, we interrogated purified HTT exon 1 proteins (Q23 or
Q43) with or without bona-fide T3 phosphorylation and ob-
served that the presence of a phosphorylated T3 residue appears
to mitigate the effect of polyQ expansion on HTT exon 1 protein
conformation. Although the effects of T3 phosphorylation on
HTT N-terminal conformation require further studies, an
N17 modification in HTT may alter the α-helicity of HTT’s N
terminus (33, 36), and indeed a phosphorylated T3 residue was
shown to modulate the α-helicity of HTT exon 1 protein (35, 36).
As temperature-dependent α-helicity as well as overall α-helicity
at any one temperature are greater in mutant HTT than in WT
HTT (24, 25), an alteration in α-helicity would be more readily
detected by the conformational TR-FRET immunoassay in
mutant HTT than in WT HTT, as indeed was observed here
(Fig. 7). Consistent with pT3 mitigating the conformational ef-
fects of polyQ expansion on an exon 1 HTT protein fragment
(36), we also observed a decreased aggregation propensity for
semisynthetic pT3 HTT exon 1 Q43 relative to its WT counter-
part (Fig. 7). Although the phosphomimetic T3D mutation was
previously reported to increase aggregation of mutant HTT exon
1 in ST14A cells and in a Drosophila HD model (39), recent
biophysical studies showed that the T3D mutation does not
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reproduce the effect of T3 phosphorylation on the structure and
aggregation of HTT EX1 (36). It is also plausible that the T3D
and T3A mutations may result in structural changes that go
beyond the simple phenocopy of the presence/absence of
T3 phosphorylation. Consistent with this hypothesis is the ob-
servation of the identical protective effects of T3A and T3D
mutations in the Drosophila HD model (39).
In conclusion, we have developed a quantitative, sensitive
immunoassay for a posttranslational modification of HTT. A
strong influence of mutant polyQ expansion on pT3-HTT levels
was uncovered across a range of preclinical models, and, im-
portantly, the presence of phosphorylation on T3 residue and
polyQ sensitivity in clinical samples was proved, therefore sup-
porting the significance of T3 phosphorylation in human HD.
Additionally, we have provided initial evidence that pT3 may
influence mutant HTT conformation and aggregation, at least in
isolated proteins in vitro. Confirmation of these initial findings in
more physiological settings requires the identification of genetic
and/or pharmacological tools to modulate HTT T3 phosphory-
lation in preclinical HD models to interrogate HTT pT3 mod-
ulation effects on mutant HTT oligomerization/aggregation and
toxicity. The availability of an immunoassay to detect HTT pT3,
reported here, opens the way for screening approaches aimed at
the identification of such tools and, potentially, for therapeutic
approaches leveraging HTT PTM modulation.
Materials and Methods
Antibodies. The MW1 antibody (developed by Paul Patterson, Caltech,
Pasadena, CA and obtained from the Developmental Studies Hybridoma
Bank) binds to the polyQ stretch of HTT; the purified form was obtained
using Protein G HP Spin Trap (catalog #28–9031-34; GE Healthcare Life Sci-
ence) following the manufacturer’s recommendations. The 2B7 and
4C9 antibodies recognize the HTT N-Term 17 amino acids and the polyP
region in exon 1 of the HTT protein, respectively (74), and were obtained
from the CHDI (Cure for Huntington’s Disease Initiative) Foundation. The
anti-pT3 antibody was previously described (35, 40). MAB2166 was supplied
by a commercial source (catalog #MAB2166; Millipore) and binds to a 15-aa
region spanning from amino acids 445 to 459 of the human HTT protein (50).
HDB4E10 antibody was distributed by Thermo Fisher Scientific and binds the
region from amino acid 1,831 to 2,131 of human HTT protein. D7F7 is a
commercial antibody supplied by Cell Signaling Technology and recognizes a
region surrounding Pro1220 of human HTT protein. The 8A4 antibody
(catalog #sc-47759) was purchased from Santa Cruz Biotechnology and binds
amino acids 2,703–2,911 of human HTT protein. Antibody against GAPDH
was distributed by Sigma-Aldrich (catalog #G9545). Secondary antibodies
used for WB were goat–anti-mouse IgG HRP-conjugated (catalog #12–349;
Merck Millipore) and goat–anti-rabbit IgG HRP-conjugated (catalog #12–
348; Merck Millipore). The D2 fluorophore and the terbium cryptate anti-
body labelings were custom made by CisBio. The Alexa-647 labeling was
performed using the Alexa Fluor-647 Monoclonal Antibody Labeling Kit
from Thermo Fisher Scientific (catalog #A20186) following the manufac-
turer’s instructions. MW1 antibody was conjugated to magnetic particles for
Singulex assays, following the manufacturer’s recommendations (catalog
#03–0077-02; Singulex).
Semisynthetic Proteins. The production of semisynthetic HTT exon 1 proteins
with relevant PTMs was described before (35, 36). Pure trifluoroacetic acid was
added to the lyophilized protein powder for disaggregation, and proteins were
then dissolved in TBS buffer (50 mM Tris 150 mM NaCl) to obtain a final con-
centration of 20 μM (pH adjusted to 7.2–7.4 using 1 M NaOH). Protein solutions
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Fig. 7. T3 phosphorylation impacts mutant HTT N-terminal conformational rigidity and decreases HTT EX1 aggregation. (A, i) T3 phosphorylation has no
effect on the conformation of soluble semisynthetic HTT EX1 Q23 protein as measured by the 2B7/MW1 TR-FRET conformational immunoassay. (A, ii)
T3 phosphorylation decreases the conformational rigidity of HTT EX1 Q43 protein assessed with the same TR-FRET. Other relevant N17 PTMs, specifically
acetylation on residues K6 and K9, do not affect the conformational rigidity of HTT EX1 Q43 protein as measured in parallel using the same assay. Summary of
three independent experiments (one-way ANOVA test; ***P < 0.005). (B) The control 2B7/4C9 TR-FRET immunoassay, the signal of which on HTT protein is not
temperature- and polyQ-dependent, is not affected by T3 phosphorylation. (C) T3 phosphorylation reduces the aggregation propensity of mutant HTT
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difference in soluble Q43 and pT3 Q43 semisynthetic protein levels is observed as measured by densitometry; however, a much larger difference in insoluble
protein levels is observed. Means and SD of three independent experiments, paired t-test (two-tailed; *P < 0.05).
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were filtered through a 100-kDa membrane (Nanosep Centrifugal Devices
100K Omega, catalog #OD100C34; Pall). Each sample was supplied with 1%
Tween-20. Dephosphorylation of protein was performed using 10 unit/μL con-
centrated alkaline phosphatase (calf intestinal phosphatase, catalog #M0290S;
New England Biolabs), following the manufacturer’s instructions.
Plasmid and Constructs. cDNAs encoding N-terminal HTT fragments (exon 1)
bearing different polyQ lengths (Q16, Q39, or Q72) were synthesized by Gen-
script, quality-controlled by DNA sequencing, and subcloned into pCDNA3.1,
and their expression in mammalian cells was validated as previously reported
(24). N17 domain mutant HTT exon 1 constructs (threonine in position 3 mu-
tated to alanine) were synthesized and validated as above. cDNAs encoding
human full-length HTT (Q18) in pCDNA3.1 were reported previously (75).
HEK293T Cell Culture and Manipulation. HEK293T cells were cultured and lysed
as previously described (24, 40). Lysis was performed 24 h after transfection
in lysis buffer (PBS, 0.4% Triton X100) supplemented with 1× protease in-
hibitor mixture (Roche). RNA interference (RNAi) was performed using
specific Huntingtin short interfering RNAs (siRNAs) (MISSION Predesigned
HTT siRNAs, Sigma-Aldrich). mRNA was extracted from HEK293T cells si-
lenced with siRNAs using RNeasy Plus Mini (catalog #74134; Qiagen), and
lysis of cells was carried out 48 h after transfection (as described above).
mRNA was reverse transcribed using the SuperScript III First-Strand Synthesis
System (catalog #18080–051; Thermo Fisher Scientific). Real-time PCR was
performed using Power SYBR Green PCR Master Mix, Applied Biosystem
(catalog# 4367659; Thermo Fisher Scientific) with specific HTT primers
(FWD 5′-GTGGAGGTTTGCTGAGCTG-3′; REV GCAAAATTGCCAAAAGAAGC;
Bio-Fab Research Srl), and an Applied Biosystems real-time PCR platform
(AbiPrism7900 HT) was used for amplification and analysis.
iPSC Culture and Sample Processing. Neuronally differentiated iPSC lines from
control individual and HD patients were generated and characterized by the E.
Cattaneo laboratory (University of Milan). The human iPSC lines used (#CTRL21:
CAG status 21/18; #CTRL28: CAG status 28/18; #CTRL33: CAG status 33/18; #HD60:
CAG status 60/18; #HD109: CAG status 109/19) are those reported in ref. 57 and
have been differentiated applying the striatal differentiation protocol in ref. 58.
The protocol was characterized for its reproducibility in human ES and iPSC lines
as extensively described in ref. 76, and the cells were harvested and immediately
stored as pellets at −80 °C. Frozen-cell pellets were lysed using lysis buffer
(composition described above) and cleared after sonication.
Animal Tissues. HD knock-in mice with increasing CAG repeat lengths were
reported previously (56, 77). For tissue preparation, 6-mo-old mice were
employed. Following dissection, mouse brain-tissue samples were homogenized
using a Fast-Prep 96 (BioMedical) in 10 vol (wt/vol) of lysis buffer (composition
described above) using PreCellys tubes, and two lysis cycles of 10 min at 6,000 × g
were carried out. Homogenates were cleared and stored at −80 °C. Tissues from
knock-in Hdh mice bearing a humanized exon 1 with different polyQ expansions
(Q7, Q20, Q50, Q92, and Q111) were obtained from the CHDI Foundation.
Human Samples. Peripheral blood lymphocytes fromcontrol andHD subjectswere
obtained as described (78), harvested by centrifugation, and snap-frozen as pel-
lets. Pellets were resuspended in lysis buffer (composition previously described),
sonicated, and finally clarified before the total protein quantification. A program
to collect biological specimens, including blood samples, at Instituto CSS-Mendel,
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Casa Sollievo
della Sofferenza for research purposes, was approved by the Ethical Committee
from the Casa Sollievo della Sofferenza Foundation, section of Istituto Tumori
Giovanni Paolo II in Bari. Informed consents were obtained from patients and
healthy control subjects.
Western Blot Assay, Filter Trap Assay, and pTag Gel. For WB, samples were
denatured at 95 °C in 4× Loading Buffer (125 mM Tris·HCl, pH 6.8, 6% SDS, 4 M
urea, 4 mM EDTA, 30% glycerol, 4% 2-mercaptoethanol and bromophenol
blue) and loaded on NuPAGE 4–12% Bis–Tris Gel (catalog #WG1402BOX;
Thermo Fisher Scientific). Proteins were transferred on PVDF membrane (catalog
#162–0177; Bio-Rad Laboratories) using wet blotting. After fixing in 0.4%
paraformaldehyde/0.4% sucrose solution and blocking with 5% nonfat milk in
TBS/0.1% Tween-20, primary antibody incubation was carried out overnight at 4
°C, and secondary antibody incubations for 1 h at room temperature. Protein
bands were detected using chemiluminescence substrate (Supersignal West
Femto Maximum catalog #3406; Supersignal West Pico Maximum catalog
#34087; Thermo Fisher Scientific) on Chemidoc XRS+ (Bio-Rad Laboratories).
For filter-trap assay, semisynthetic proteins were diluted in TBS/1% SDS.
Vacuum filtration of samples was performed through a 96-well dot-blot
apparatus (Bio-Dot Apparatus #1706545; Bio-Rad Laboratories) containing
a 0.2-μM cellulose acetate membrane filter (catalog #10404180; Whatman)
prewetted in TBS/1% SDS. After two washing steps with TBS/1% SDS, the
membrane was fixed, blocked, and incubated with antibodies as previously
described (63). For Phos-Tag gel analysis, cell lysates were prepared and run
as previously described (40).
Immunoprecipitation. Immunoprecipitation was performed using Dynabeads
Protein G (catalog #10004D; Thermo Fisher Scientific) following the manu-
facturer’s instructions and using an HTT-specific antibody (2B7) or an un-
related antibody (GFAP, catalog #G9269; Sigma- Aldrich). The pulled-down
material was loaded on a SDS/PAGE, and the supernatant (immunodepleted
sample) was analyzed by Singulex assay.
Singulex Assays. A total of 50 μL/well of dilution buffer (6% BSA, 0.8% Triton
X-100, 750 mM NaCl, and complete protease inhibitor) was added to a 96-well
plate (catalog #P-96–450V-C; Axygen). Samples to be tested were diluted in ar-
tificial cerebral spinal fluid (0.3 M NaCl; 6 mM KCl; 2.8 mM CaCl2-2H2O; 1.6 mM
MgCl2-6H20; 1.6 mM Na2HPO4-7H2O; 0.4 mM NaH2PO4-H2O) supplemented
with 1% Tween-20 and complete protease inhibitor in a final volume of 150 μL/
well. Finally, 100 μL/well of the MW1 antibody coupled with magnetic particles
(appropriately diluted in Erenna Assay buffer, catalog #02–0474-00; Singulex)
was added to the assay plate and incubated for 1 h at room temperature under
orbital shaking. The beads were then washed with Erenna System buffer (cat-
alog #02–0111-00; Singulex) and resuspended using 20 μL/well of the specific
detection antibody labeled with D2 fluorophore (or Alexa-647 fluorophore)
appropriately diluted in Erenna Assay buffer. The plate was incubated for 1 h at
room temperature under shaking. After washing, the beads were resuspended
and transferred to a new 96-well plate. A total of 10 μL/well of Erenna buffer B
(catalog #02–0297-00; Singulex) was added to the beads for elution and in-
cubated for 5 min at room temperature under orbital shaking. The eluted
complex was magnetically separated from the beads and transferred to a 384-
well plate (Nunc catalog #264573; Sigma-Aldrich) where it was neutralized with
10 μL/well of Erenna buffer D (catalog #02–0368-00; Singulex). Finally, the 384-
well plate was heat-sealed and analyzed with the Erenna Immunoassay System.
TR-FRET Assays. A total of 5 μL/well of samples and 1 μL/well of antibody
mixtures (2B7-Tb 1 ng/μL; MW1-D2 10 ng/μL; 4C9-Alexa647 10 ng/μL) were
diluted in lysis buffer (composition described above), and the assay was
performed as described (24).
Data Analysis. See SI Materials and Methods.
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